TY - STD TI - Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46. discussion 846–838. ID - ref1 ER - TY - STD TI - Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg. 1992;215(3):231–6. ID - ref2 ER - TY - STD TI - Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255(1):103–8. ID - ref3 ER - TY - STD TI - Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751–6. ID - ref4 ER - TY - STD TI - Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–33. ID - ref5 ER - TY - STD TI - Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95. ID - ref6 ER - TY - STD TI - Katz MG, Shi Q, Ahmad SA, et al. Preoperative modified folfirinox treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial a021101. JAMA Surgery. 2016;151(8):e161137. ID - ref7 ER - TY - STD TI - Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56. ID - ref8 ER - TY - STD TI - Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. ID - ref9 ER - TY - STD TI - Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. ID - ref10 ER - TY - STD TI - O'Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260(1):142–8. ID - ref11 ER - TY - STD TI - Marsh Rde W, Zhang S, Baker M, et al. Peri-operative modified FOLFIRINOX in resectable pancreatic cancer: a pilot study. J Clin Oncol. 2016;34(suppl; abstr 4103). ID - ref12 ER - TY - STD TI - Rose JB, Rocha FG, Alseidi A, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014;21(5):1530–7. ID - ref13 ER - TY - STD TI - Rao AD, Sugar EA, Chang DT, et al. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Pract Radiat Oncol. 2016;6(6):417–24. ID - ref14 ER - TY - STD TI - Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. Apr 01 2015;121(7):1128–37. ID - ref15 ER - TY - STD TI - Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015(0):1–7. ID - ref16 ER - TY - STD TI - Operative standards for cancer surgery: presented by the American College of Surgeons and the Alliance for Clinical Trials in Oncology. Vol 1. Philadelphia: Wolters Kluwer; 2015. ID - ref17 ER - TY - STD TI - Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. ID - ref18 ER - TY - BOOK AU - Edge, S. B. PY - 2010 DA - 2010// TI - American joint Committee on cancer. AJCC cancer staging manual. 7th ed PB - Springer CY - New York ID - Edge2010 ER - TY - BOOK AU - Washington, K. AU - Berlin, J. AU - Branton, P. PY - 2013 DA - 2013// TI - Burgart L PB - Carter DK CY - Compton CC. Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas ID - Washington2013 ER - TY - STD TI - Chatterjee D, Katz MH, Rashid A, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118(12):3182–3190. ID - ref21 ER - TY - STD TI - National Cancer Institute (U.S.). Common terminology criteria for adverse events (CTCAE). Rev. ed. Bethesda: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009. ID - ref22 ER - TY - STD TI - Innocenti F, Owzar K, Cox NL, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012;18(2):577–584. ID - ref23 ER - TY - JOUR AU - Koay, E. J. PY - 2014 DA - 2014// TI - Transport properties of pancreatic cancer describe gemcitabine delivery and response JO - Journal of Clinical Investigations VL - 124 UR - https://doi.org/10.1172/JCI73455 DO - 10.1172/JCI73455 ID - Koay2014 ER -